[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"AZ Sint-Lucas Gent\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":53},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":5},"100650945","validation-of-a-circulating-tumor-dna-blood-test-in-muscle-invasive-bladder-and-upper-tract-urothelial-cancer-100650945",false,"NCT07756437","Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer","Internal Validation of Circulating Tumor DNA (ctDNA) Sequencing in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma: A Prospective Observational Study","BLUT-DNA","Inclusion Criteria:\n\n* Age 18 years or older.\n* Histologically confirmed muscle-invasive bladder cancer or suspected muscle-invasive upper tract urothelial carcinoma, stage T2 or higher.\n* Availability of tumor tissue from transurethral resection of bladder tumor, ureteroscopic biopsy, biopsy of a metastatic lesion, or nephroureterectomy for DNA extraction.\n* Written informed consent provided.\n\nExclusion Criteria:\n\n\\- Concurrent active malignancy diagnosed within the past 5 years.","ALL","18 Years",{"count":20,"type":21},70,"ESTIMATED","OBSERVATIONAL","This prospective observational study evaluates a blood-based circulating tumor DNA (ctDNA) test in patients with muscle-invasive bladder cancer or upper tract urothelial cancer. ctDNA consists of small fragments of tumor DNA that can sometimes be detected in the blood.\n\nIn this study, DNA from tumor tissue obtained during routine diagnostic or surgical procedures will be analyzed to identify tumor-specific mutations. Blood samples collected during routine clinical care will then be tested to determine whether the same mutations can be detected in plasma ctDNA.\n\nThe main purpose is to assess how well the internally developed ctDNA assay detects tumor-specific mutations compared with tumor tissue sequencing. The study will also explore whether ctDNA results after treatment are associated with recurrence or remission during two years of follow-up, and whether changes in ctDNA levels during treatment are associated with pathological response.\n\nThis study does not assign participants to a treatment and does not require additional blood draws beyond routine care. Treating physicians will remain blinded to ctDNA results during the study, so the test results will not influence clinical decisions.",[25,26,27],"Muscle-Invasive Bladder Cancer (MIBC)","Upper Tract Urothelial Carcinoma","Urothelial Carcinoma (UC)",[29,30,31,32,33,34,35,26,36,37,38,39,40],"Circulating Tumor DNA","ctDNA","Liquid biopsy","Tumor-Informed Sequencing","Minimal Residual Disease","MRD","Muscle-Invasive Bladder Cancer","Urothelial carcinoma","Next-Generation Sequencing","NGS","Recurrence Monitoring","Treatment response","RECRUITING","2026-08-05",{"date":44,"type":45},"2026-08-10","ACTUAL",{"date":47,"type":45},"2025-11-07",{"date":49,"type":21},"2029-06-01",{"name":51,"class":52},"AZ Sint-Lucas Gent","OTHER",""]